Home » Technology » The Company at the Forefront of the Genetic Medicine Revolution
Building the Bioeconomy

The Company at the Forefront of the Genetic Medicine Revolution

Man in lab pointing at Ipad
Man in lab pointing at Ipad

James Taylor

Co-Founder & CEO, Precision NanoSystems

In the nearly two decades since the human genome was first sequenced, there has been an explosion of insights into the role genes play in a vast array of diseases. These insights are implemented when creating genetic medicines, in designing RNA or DNA molecules and then delivering those molecules to affected cells. This treats disease by turning off disease-causing genes, replacing genes that are missing or incorrect, or directly repairing an issue in a patient’s genome. Genetic medicine is a promising new class of medicine that wasn’t possible even a short time ago.

Genetic vaccines are an important type of genetic medicine and are a leading class of vaccines being developed for COVID-19. These deliver RNA or DNA via a lipid nanoparticle (LNP) carrier to the recipient’s cells to produce representative but harmless parts of viral antigens that teach the immune system how to recognize and fight the given pathogen. Genetic vaccines are faster to develop and manufacture than conventional vaccines and are a very promising technology for pandemic response.

Vancouver-based Precision NanoSystems Inc. (PNI) is a leading supplier of genetic vaccine and therapeutic manufacturing technologies and services. PNI was founded to solve a significant challenge in manufacturing genetic medicines. Through our proprietary NanoAssemblr manufacturing platform, LNP gene delivery technology, and strategic partnerships with bio-processing technology providers, we have established ourselves as a comprehensive solution provider in the genetic medicine industry.

Genetic vaccines are an important type of genetic medicine and are a leading class of vaccines being developed for COVID-19.

Enabling genetic medicines globally

Since PNI’s founding in 2010, we have made significant strides in the development, commercialization, and market adoption of our NanoAssemblr microfluidic-based manufacturing platform and our GenVoy LNP technology. This has enabled genetic medicine developers across the world to easily adopt crucial gene delivery technologies.

With more than 450 instruments installed worldwide — in 19 of the top 25 pharmaceutical companies, at more than 120 companies, and at 90 academic research institutes — PNI is ensuring our NanoAssemblr systems and innovations pervade the global biotechnology ecosystem. We provide access to our research facilities, technical personnel, and technologies for custom drug development and manufacturing process development to global clients through our contract service offerings.

 

PNI is a driver of the genetic medicine revolution

PNI is supporting drug developers to translate transformative medicines to patients through the manufacturing of genetic medicines under the good manufacturing practices required for human administration. Our technology enables the translation of drug candidates from the bench to the clinic faster and at a lower risk than was previously possible.

PNI’s mission is to accelerate the creation of transformative medicine and to bring life-changing medicines to patients. Our NxGen technology and expertise have accelerated the development of genetic vaccines and therapeutic platforms, and most of PNI’s clients are continuing to develop advanced medicines. Through our innovations, PNI is enabling the next wave of medicines in infectious diseases, cancer, rare diseases, and others.

Next article